JP2012506695A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506695A5
JP2012506695A5 JP2011523864A JP2011523864A JP2012506695A5 JP 2012506695 A5 JP2012506695 A5 JP 2012506695A5 JP 2011523864 A JP2011523864 A JP 2011523864A JP 2011523864 A JP2011523864 A JP 2011523864A JP 2012506695 A5 JP2012506695 A5 JP 2012506695A5
Authority
JP
Japan
Prior art keywords
seq
antibody
heavy chain
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053425 external-priority patent/WO2010021874A2/en
Publication of JP2012506695A publication Critical patent/JP2012506695A/ja
Publication of JP2012506695A5 publication Critical patent/JP2012506695A5/ja
Pending legal-status Critical Current

Links

JP2011523864A 2008-08-20 2009-08-11 改変された抗il−13抗体、組成物、方法、及び使用 Pending JP2012506695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9047208P 2008-08-20 2008-08-20
US61/090,472 2008-08-20
US9723208P 2008-09-16 2008-09-16
US61/097,232 2008-09-16
PCT/US2009/053425 WO2010021874A2 (en) 2008-08-20 2009-08-11 Engineered anti-il-13 antibodies, compositions, methods and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012182330A Division JP2013005805A (ja) 2008-08-20 2012-08-21 改変された抗il−13抗体、組成物、方法、及び使用

Publications (2)

Publication Number Publication Date
JP2012506695A JP2012506695A (ja) 2012-03-22
JP2012506695A5 true JP2012506695A5 (https=) 2012-09-27

Family

ID=41707613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011523864A Pending JP2012506695A (ja) 2008-08-20 2009-08-11 改変された抗il−13抗体、組成物、方法、及び使用
JP2012182330A Pending JP2013005805A (ja) 2008-08-20 2012-08-21 改変された抗il−13抗体、組成物、方法、及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012182330A Pending JP2013005805A (ja) 2008-08-20 2012-08-21 改変された抗il−13抗体、組成物、方法、及び使用

Country Status (20)

Country Link
US (2) US8399630B2 (https=)
EP (1) EP2328615A2 (https=)
JP (2) JP2012506695A (https=)
KR (1) KR20110043786A (https=)
CN (1) CN102264391A (https=)
AR (1) AR073088A1 (https=)
AU (1) AU2009283008A1 (https=)
BR (1) BRPI0917370A2 (https=)
CA (1) CA2734645A1 (https=)
CO (1) CO6341573A2 (https=)
CR (1) CR20110152A (https=)
EA (1) EA201170357A1 (https=)
EC (1) ECSP11010840A (https=)
IL (1) IL211087A0 (https=)
MX (1) MX2011001909A (https=)
NI (1) NI201100040A (https=)
NZ (1) NZ591098A (https=)
UY (1) UY32060A (https=)
WO (1) WO2010021874A2 (https=)
ZA (1) ZA201102081B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EA201170357A1 (ru) * 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP2013508287A (ja) * 2009-10-14 2013-03-07 ヤンセン バイオテツク,インコーポレーテツド 抗体を親和性成熟する方法
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2018148595A1 (en) 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506574B1 (fr) 1991-03-29 1995-11-29 Sanofi Protéine à activité de type cytokine, ADN recombinant codant pour cette protéine, cellules et microorganismes transformés
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2001023410A2 (en) 1999-09-28 2001-04-05 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002101629A1 (en) 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
JP2007525458A (ja) * 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−1(IFNAR−1)に対するヒト化抗体
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
EP1713441A2 (en) 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
JP2010502224A (ja) * 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン13結合タンパク質
WO2008052108A2 (en) 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
BRPI0720280A2 (pt) * 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EA201170357A1 (ru) * 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение

Similar Documents

Publication Publication Date Title
JP2012506695A5 (https=)
RU2650767C2 (ru) Интерлейкин-13-связывающие белки
CN113286814A (zh) 多价调节性t细胞调节子
JP2008502366A5 (https=)
CN110105451B (zh) IL-4Rα抗体及其用途
WO2022033538A1 (zh) Il-11的抗体及其应用
AU2005229009A1 (en) Monoclonal antibodies specific for human OX40L (CD 134L)
CN104105704A (zh) Il4/il13结合重复蛋白及用途
CN101522716A (zh) 抗人il-4受体的高亲和力人抗体
CA2626214C (en) Novel use of il-1beta compounds
JP2013005805A (ja) 改変された抗il−13抗体、組成物、方法、及び使用
CN101932935A (zh) 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
JP2025532685A (ja) Tslp及びil4rを標的とする組換え二重特異性抗体
WO2019148405A1 (zh) IL-4Rα抗体及其用途
KR102558891B1 (ko) 항―il4―il13 2특이성 항체
WO2022186772A1 (en) TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2013103783A1 (en) Murine il-13 antibodies
AU2022229076A1 (en) TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
JP5476310B2 (ja) hGM−CSFに結合するモノクローナル抗体および前記抗体を含む医薬組成物
EP4590692A1 (en) Bi-specific agent for targeted plasma cell-depletion and treatment of anti-viral immunodeficiency
TW202540182A (zh) 用於治療代謝疾病之新穎抗體和抗體共軛體
WO2024028509A2 (en) Treatment of an inflammation-associated disease in a patient expressing high chemerin level
HK40123789A (zh) 优化的抗tl1a抗体
HK40052681A (en) Multivalent regulatory t cell modulators
HK40042163B (zh) 优化的抗tl1a抗体